ClinicalTrials.gg
RecruitingNCT04651010PIMISUTTUpdated Oct 13, 2026

Predictive Multimodal MRI Factors in Subacute Cerebral Artery Occlusiontreated by Thrombectomy (PIMISUTT)

An interventional study of Multimodal MRI in Middle Cerebral Artery Acute Ischemic Stroke, sponsored by Poitiers University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.
Updated Oct 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 164 studies in Ischemic Stroke with a site in France — 56 open to participants now, 61 under way, 10 of them phase 3. Ischemic Stroke · France.

Planned enrollment
77th of 109
50 · median 186
Started
2021
with 12 others
No phase
58 of 164
23 open now
Primary completion
2028-08
later than 44 of 60 live
Registered
81st of 164
by date

Among the 164 studies in Ischemic Stroke with a site in France, this one is the 77th largest by planned enrollment of the 109 interventional ones that give a count, is one of 13 that started in 2021, is one of 58 with no phase, reaches primary completion later than 44 of the 60 other live ones, and was the 81st registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

56 of the 164 studies in Ischemic Stroke with a site in France are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Ischemic Stroke with a site in France, or all of them as a file.
02

Study summary

Our study aims to measure metabolic and functional parameters of the infarcted territory by multimodal cerebral MRI in patients diagnosed with unilateral proximal occlusion of the middle cerebral artery and treated by thrombectomy in order to correlate those parameters to clinical outcome (evaluated by modified Rankin score) at 3 months.

We aim to find early radiologic predictive factors for favorable clinical outcome in this population of patients.

Read the detailed description

The treatment of acute ischemic stroke in the setting of intracranial large artery occlusion and especially middle cerebral artery occlusion (MCAO) with intravenous tissue plasminogen activator (IV-tPA) is associated with low rates of recanalization and high rates of neurological morbidity and functional dependence.

In the last few years, endovascular intervention (mechanical thrombectomy) has proven its safety and its efficacy on clinical outcome in patients diagnosed with MCAO and is now commonly recommended.

However, in this population of patients treated by thrombectomy, very few predictive factors, except for the post-procedural recanalization score (TICI), do exist to foresee the variability of clinical outcome.

Tissue viability of the infarcted territory can be approached by the measure of metabolic and morphological parameters (Na+, H+, phosphore, diffusion imaging) which can be non-invasively done by multimodal MRI, as suggest by recently published studies.

Our study plans to measure these parameters between 12 and 24 hours after acute ischemic stroke in patients with MCAO treated by thrombectomy in order to correlate those parameters to clinical outcome at 3 months (modifier Rankin Score).

03

Conditions studied

  • Middle Cerebral Artery Acute Ischemic Stroke

Browse trials for

Keywords

  • Ischemic stroke
  • acute middle cerebral artery occlusion
  • multimodal MRI
  • thrombectomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged ≥ 18 years old
  • Hospitalized at the Poitiers University Hospital
  • Acute middle cerebral artery occlusion diagnosed by CT-scan or MRI
  • NIHSS score ≥ 6 at admission
  • To be treated by thrombectomy with or without fibrinolysis
  • Written information delivered to the patient or his relatives concerning the study and its benefit and risk

Exclusion criteria

Exclusion Criteria:

  • Patients or relatives whom a loyal information about the study cannot be given
  • Patient with cognitive impairments before MRI.
  • Patients who cannot undergo MRI because of
  • Patients too deteriorated to tolerate one hour long exam
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Multimodal MRI

    Other: Multimodal MRI

Interventions

  • OtherMultimodal MRI

    Multimodal MRI will be realized between 12 and 24 hours after thrombectomy

06

What researchers measure

Primary outcomes

  1. Correlation between modified Rankin score at 3 months and multimodal MRI data

    Time frame: Month 3

Secondary outcomes

  1. Discharge National Institute of Health Stroke Score (NIHSS)

    Time frame: Month 3

  2. National Institute of Health Stroke (NIHSS) score at 3 months

    Time frame: Month 3

  3. Change in NIHSS score at 3 months compared to post-thrombectomy

    Time frame: Month 3

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Aug 2028, 81 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 81 months is above that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Aug 2026 → Aug 2028 and completion Aug 2026 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2020
First posted
Dec 3, 2020
StartActual
Nov 15, 2021
Primary completionEst.
Aug 15, 2028was Aug 2026
CompletionEst.
Aug 15, 2028was Aug 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 15, 2026→Aug 15, 2028
Oct 13, 2026
Study completion
Aug 15, 2026→Aug 15, 2028
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Aug 15, 2026→Aug 15, 2028
    Study completion Aug 15, 2026→Aug 15, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04651010
Responsible party
Sponsor
First posted
Dec 3, 2020
Start date
Nov 15, 2021
Primary completion
Aug 15, 2028 (estimated)
Completion
Aug 15, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Guillaume HERPE, Dr
Contact
guillaume.herpe@chu-poitiers.fr
05 49 44 33 89
Céline DELETAGE
Contact
celine.deletage@chu-poitiers.fr
05 49 44 38 54 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion